DynaMed vs OpenEvidence (2026)
Subscription against advertising, and that is the honest frame for this comparison rather than a feature contest. DynaMed is a curated corpus built under a stated seven step methodology with a named editorial team, funded by subscriptions, with its generative layer bounded to its own content and labelled as generative. OpenEvidence is free to verified United States clinicians and paid for by pharmaceutical and device advertising, with a corpus reaching current primary literature through named partnerships with the New England Journal of Medicine, JAMA and Cochrane. On evidence OpenEvidence is unexpectedly ahead: a systematic review identified eleven independent studies evaluating it between 2024 and 2026, which is more external scrutiny than any incumbent here has attracted. On the question of whether a commercial relationship can sit next to a clinical answer, DynaMed has nothing to explain and OpenEvidence has a published policy you should read.
- The corpus is bounded and the vendor says so: a retrieval augmented framework over its own DynaMed, DynaMedex and Dynamic Health content, with generative output labelled as generative and a published principle limiting generative use in user facing applications.
- An Epic App Orchard marketplace listing from June 2021, which is a reviewed integration credential rather than a partnership claim, plus institutional single sign on and multi organisation affiliation for one clinician.
- No advertising anywhere in the product. Content is funded by subscription, so nothing in the answer path carries a commercial relationship with a manufacturer whose product might be the answer.
- The independent literature is deeper than for anything else in this category and the vendor did not commission it: a systematic review following PRISMA identified eleven studies published between 2024 and 2026 evaluating this product.
- The corpus reaches current primary literature through named partnerships with the New England Journal of Medicine, JAMA and its eleven specialty journals, and Cochrane Systematic Reviews, rather than through a publisher's own back catalogue.
- It is free to verified United States clinicians, with web and native mobile applications and enterprise deployment embedded in Epic, documented at Mount Sinai across seven hospitals.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. DynaMed and OpenEvidence are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | DynaMed | OpenEvidence |
|---|---|---|
| Primary category | Clinical Reference & Evidence | Clinical Reference & Evidence |
| Founded | Not recorded | 2021 |
| Headquarters | Ipswich, Massachusetts | Miami, Florida |
| Website | dynamed.com | openevidence.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards DynaMed its top capability grade on EHR and Interoperability Depth. Set against OpenEvidence, DynaMed grades higher on several axes, including Model and Technology Transparency, AI Governance and Bias Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards OpenEvidence its top capability grade on AI Centrality and Security Certifications and Trust Center. Set against DynaMed, OpenEvidence grades higher on AI Centrality, HIPAA and BAA Posture and Security Certifications and Trust Center. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose DynaMed or OpenEvidence?
On the axes where the AI Health Index separates them, DynaMed grades higher on several axes, including Model and Technology Transparency, AI Governance and Bias Disclosure and AI Liability and Recourse, and OpenEvidence grades higher on AI Centrality, HIPAA and BAA Posture and Security Certifications and Trust Center. DynaMed leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do DynaMed and OpenEvidence differ most?
The widest separation the AI Health Index records between DynaMed and OpenEvidence is on AI Centrality, where DynaMed grades C and OpenEvidence grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do DynaMed and OpenEvidence grade the same?
The AI Health Index grades DynaMed and OpenEvidence the same on several axes, including Autonomy and Oversight Model, Model Supply Chain Disclosure and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have DynaMed and OpenEvidence not disclosed?
At the last review, at least one of DynaMed and OpenEvidence published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
OpenEvidence is monetised through pharmaceutical and medical device advertising presented alongside clinical answers, which is a structural conflict of interest that no amount of policy removes. The company publishes an advertising policy governing it, which is more than most advertising funded clinical products offer, and a buyer should read that policy rather than take the disclosure on trust.
DynaMed publishes no security attestation, trust centre, penetration testing cadence or vulnerability disclosure programme across two retrieval passes, and its HIPAA position is asserted rather than evidenced. Neither vendor publishes a bias evaluation, subgroup analysis or error taxonomy for its generative layer.